Literature DB >> 12491508

Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma.

Keiichi Isaka1, Hirotaka Nishi, Hiromi Nakai, Toshihide Nakada, Yin Feng Li, Yoshiro Ebihara, Masaomi Takayama.   

Abstract

BACKGROUND: The human matrix metalloproteinase (MMP)-26, also called matrilysin-2 or endometase, has been isolated as a matrilysin (MMP-7) homolog. Matrix metalloproteinase-26 was expressed in tissue samples from the placenta and endometrial tumors and its expression may be related to the development of endometrial carcinomas.
METHODS: Total RNAs were isolated from 5 endometrial carcinoma cell lines, 36 normal endometrial tissue samples, 4 hyperplasia tissue samples, and from 24 endometrial carcinoma tissue samples. Reverse transcription-polymerase chain reation (RT-PCR) was performed to detect MMP-26 mRNA expression. To identify MMP-26 mRNA localization and protein expression, we performed in situ RT-PCR and immunohistochemistry, respectively.
RESULTS: Reverse transcription-polymerase chain reaction analysis revealed that MMP-26 mRNA was expressed in 24 of 36 normal human endometrial tissue samples. However, MMP-26 mRNA expression was not detected in endometrial carcinoma cell lines nor in endometrial carcinoma tissue samples except for one case. Western blot analysis showed similar results. In situ RT-PCR analysis revealed that MMP-26 expression was localized in the epithelial glandular cells but faint expression was observed in the stromal cells. Subsequently, we separated endometrial tissues into epithelial glandular and stromal cells. Using RT-PCR, the purified epithelial glandular cells exhibited MMP-26 mRNA expression but the purified stromal cells did not. Immunohistochemical analyses revealed that MMP-26 protein expression is also limited to endometrial epithelial glandular cells but not to cancer cells. Therefore, MMP-26 expression is limited to normal epithelial glandular cells.
CONCLUSIONS: We found a significant difference in MMP-26 expression in normal and malignant endometrial tissue samples, although its function is still unknown. These data suggest that MMP-26 may be a candidate for a new tumor marker for endometrial carcinomas. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12491508     DOI: 10.1002/cncr.11030

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  MMP26: A potential biomarker for prostate cancer.

Authors:  Teng Cheng; Fei Li; Rui Wei; Meng-Qin Lv; Yin Zhou; Yun Dai; Yuan Yuan; Gui-Ying Jiang; Ding Ma; Qing-Lei Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

2.  Matrix metalloproteinases in serum and the follicular fluid of women treated by in vitro fertilization.

Authors:  Petra Horka; Karin Malickova; Radka Jarosova; Ivana Janatkova; Tomas Zima; Marta Kalousova
Journal:  J Assist Reprod Genet       Date:  2012-09-28       Impact factor: 3.412

Review 3.  Matrix metalloproteinases: protective roles in cancer.

Authors:  Julie Decock; Sally Thirkettle; Laura Wagstaff; Dylan R Edwards
Journal:  J Cell Mol Med       Date:  2011-06       Impact factor: 5.310

4.  Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.

Authors:  Andrea Schröpfer; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Sonja Feix; Jelena Anacker
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

5.  Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls.

Authors:  Sonja Boyd; Kalle Tolvanen; Susanna Virolainen; Tiina Kuivanen; Lauri Kyllönen; Ulpu Saarialho-Kere
Journal:  Virchows Arch       Date:  2007-11-22       Impact factor: 4.064

6.  Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values.

Authors:  Laura Mäkitalo; Taina Sipponen; Päivi Kärkkäinen; Kaija-Leena Kolho; Ulpu Saarialho-Kere
Journal:  Int J Colorectal Dis       Date:  2009-08-04       Impact factor: 2.571

7.  Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer.

Authors:  V O Bister; M T Salmela; M L Karjalainen-Lindsberg; J Uria; J Lohi; P Puolakkainen; C Lopez-Otin; U Saarialho-Kere
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

8.  MiR-125b regulates endometrial receptivity by targeting MMP26 in women undergoing IVF-ET with elevated progesterone on HCG priming day.

Authors:  Cheng Chen; Yue Zhao; Yang Yu; Rong Li; Jie Qiao
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.